Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.

Publication ,  Journal Article
Armbruster, SD; Previs, R; Soliman, PT; Westin, SN; Fellman, B; Jhingran, A; Fleming, ND
Published in: Gynecol Oncol
August 2019

OBJECTIVE: To evaluate clinicopathologic factors and adjuvant treatment effects on recurrence free (RFS) and overall survival (OS) in early stage uterine clear cell carcinoma (UCCC). METHODS: Our retrospective review included central pathology confirmed stage I or II UCCC treated and/or followed between 2000 and 2016. Cases with pure or mixed histology with >50% UCCC were included. Data were analyzed using Kaplan-Meier method and Cox proportional hazards regressions. RESULTS: 112 women were identified. Median age was 65.5 years (range 34-94). Most patients had mixed UCCC (61%), while 39% had pure UCCC. The majority of patients had stage IA UCCC (66%) versus stage IB (15%) or stage II (18%) disease. Adjuvant treatment included chemotherapy + radiation (26%), brachytherapy (27%), whole pelvic radiation (15%), chemotherapy alone (8%), and observation (24%). Thirty-eight (34%) women had recurrent disease. Median RFS was 4.32 years (95% CI 2.77-5.78). On multivariate analysis, age ≥70 (HR 2.48, 95% 1.28-4.81) and positive LVSI (HR 2.19, 95% CI 1.15-4.18) were associated with shorter RFS. Median OS was 9.8 years (95% CI 7.46-15.93). On multivariate analyses, age ≥70 (HR 3.57, 95% CI 1.64-7.74) and positive LVSI (HR 2.46, 95% CI 1.12-5.37) were associated with shorter OS. In this retrospective descriptive uncontrolled patient series, adjuvant treatment type did not impact RFS or OS. CONCLUSIONS: OS approaches 10 years for early stage UCCC patients. Women ≥70 years have worse PFS and OS regardless of treatment modality, encouraging consideration of quality of life implications when electing for adjuvant therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

August 2019

Volume

154

Issue

2

Start / End Page

328 / 332

Location

United States

Related Subject Headings

  • Watchful Waiting
  • Uterine Neoplasms
  • Retrospective Studies
  • Radiotherapy, Adjuvant
  • Proportional Hazards Models
  • Oncology & Carcinogenesis
  • Middle Aged
  • Longitudinal Studies
  • Kaplan-Meier Estimate
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armbruster, S. D., Previs, R., Soliman, P. T., Westin, S. N., Fellman, B., Jhingran, A., & Fleming, N. D. (2019). Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. Gynecol Oncol, 154(2), 328–332. https://doi.org/10.1016/j.ygyno.2019.06.001
Armbruster, Shannon D., Rebecca Previs, Pamela T. Soliman, Shannon N. Westin, Bryan Fellman, Anuja Jhingran, and Nicole D. Fleming. “Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.Gynecol Oncol 154, no. 2 (August 2019): 328–32. https://doi.org/10.1016/j.ygyno.2019.06.001.
Armbruster SD, Previs R, Soliman PT, Westin SN, Fellman B, Jhingran A, et al. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. Gynecol Oncol. 2019 Aug;154(2):328–32.
Armbruster, Shannon D., et al. “Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.Gynecol Oncol, vol. 154, no. 2, Aug. 2019, pp. 328–32. Pubmed, doi:10.1016/j.ygyno.2019.06.001.
Armbruster SD, Previs R, Soliman PT, Westin SN, Fellman B, Jhingran A, Fleming ND. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. Gynecol Oncol. 2019 Aug;154(2):328–332.
Journal cover image

Published In

Gynecol Oncol

DOI

EISSN

1095-6859

Publication Date

August 2019

Volume

154

Issue

2

Start / End Page

328 / 332

Location

United States

Related Subject Headings

  • Watchful Waiting
  • Uterine Neoplasms
  • Retrospective Studies
  • Radiotherapy, Adjuvant
  • Proportional Hazards Models
  • Oncology & Carcinogenesis
  • Middle Aged
  • Longitudinal Studies
  • Kaplan-Meier Estimate
  • Humans